Navigation Links
Outbreaks of Whooping Cough Contributed by Vaccine Exemptions

lso grant exemptions for medical reasons. In addition, nearly all states also allow exemptions for religious beliefs, while 19 grant waivers for personal beliefs.

The study found that in these latter states an increasing number of parents have been opting out of vaccination in recent years. On an average, the rate of non-medical exemptions grew by 6 percent per year between 1991 and 2004.

Salmon reported that parents usually claim such exemptions on the grounds of concerns about vaccine safety. His earlier studies have shown that 69 percent of those parents who sought exemptions did so because they feared vaccination did more harm than the diseases it prevents.

These concerns mostly stem from proposed link between the MMR vaccine and autism, a link which has now been refuted by several international studies.

Salmon and his colleagues argue that states should have "administrative controls" that make non-medical exemptions more difficult to obtain. This, Salmon said, could look something like the process of becoming a conscientious objector to the draft.

He explained that the government would either have to demonstrate an "overwhelming need" for universal vaccination or grant the exemption.
NLA
'"/>




Page: 1 2

Related medicine news :

1. Grapes, Melons Implicated in Outbreaks
2. Needle-Free Injection System Ideal for Pandemic Outbreaks
3. Lack of Funds in Sudan-Pathway to Epidemic Outbreaks
4. Angola Warned of Recurrent Cholera Outbreaks
5. Early Warning System To Predict Zoonotic Outbreaks
6. Prime Minister Calls For Early Warning System On Epidemic Outbreaks
7. Expect More Outbreaks in Europe, Bird Flu Expert Warns
8. PAHO Urges Readiness for Dengue Outbreaks in 2007
9. Mathematical Model Predicts Cholera Outbreaks
10. AMA Calls For Calm Approach To Aged Care Illness Outbreaks
11. Rising Rates of Whooping Cough in Idaho
Post Your Comments:
Breaking Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2AMA Grants New Category III CPT Code to Premier Hearts Multifunction CardioGram 28TM 29 28MCG 29 51426 1AMA Grants New Category III CPT Code to Premier Hearts Multifunction CardioGram 28TM 29 28MCG 29 51426 2Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 1Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 2Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 3PR Whiz Belinda Foster Launches Michael Jacksons Nurse Cherilyn Lee on World Media Campaign 51425 1PR Whiz Belinda Foster Launches Michael Jacksons Nurse Cherilyn Lee on World Media Campaign 51425 2
Other Medicine Technology:Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 2Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 3Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 10